What is the appropriate antihypertensive regimen for a patient who is six months post‑stroke, being managed at home, without heart failure or contraindications?

Antihypertensive Management for Post-Stroke Patients at 6 Months

For a patient 6 months post-stroke being managed at home, initiate or optimize antihypertensive therapy with an ACE inhibitor (or ARB if ACE inhibitor not tolerated) combined with a thiazide-like diuretic, targeting blood pressure <130/80 mmHg. 1, 2

Treatment Algorithm

Step 1: Initiate Combination Therapy

• Start with ACE inhibitor + thiazide-like diuretic at low doses 2
• If ACE inhibitor causes cough or is not tolerated, substitute with ARB 3
• This combination has compelling indication for secondary stroke prevention 2, 3

Step 2: Titration Strategy

• Increase to full doses if BP target not achieved within 3 months 1
• Add a dihydropyridine calcium channel blocker (DHP-CCB) as third agent if needed 1
• The combination of ACE inhibitor + dihydropyridine CCB is preferable to ACE inhibitor + diuretic in selected high-risk patients 2

Step 3: Resistant Hypertension Management

If BP remains uncontrolled on triple therapy:

• Add spironolactone 25-50 mg daily as fourth agent 4, 5
• Alternative fourth agents if spironolactone not tolerated: amiloride, doxazosin, eplerenone, or beta-blocker 1, 5

Blood Pressure Targets

Target BP: <130/80 mmHg 1

• The 2020 ISH guidelines specifically recommend this lower target for patients with cardiovascular disease including stroke 1
• Older guidelines suggested <140/90 mmHg 2, 3, but more recent evidence supports tighter control
• Individualize for elderly patients based on frailty, but don't use this as excuse to undertreate 1

Critical Timing Considerations

Strong consideration should be given to initiating antihypertensive therapy after the acute phase of stroke 2. At 6 months post-stroke, you are well beyond the acute phase where BP management is controversial. The acute phase concerns (first 72 hours to 2 weeks) about potentially worsening cerebral perfusion no longer apply 2, 6.

Key Evidence Points

The Canadian guidelines explicitly state that antihypertensive treatment should be initiated after the acute stroke phase (Grade A recommendation) 2. The PROGRESS trial demonstrated that ACE inhibitor + diuretic combination reduced stroke recurrence by 28% and major vascular events by 26% in patients with prior cerebrovascular disease 7.

Common Pitfalls to Avoid

1. Don't avoid ACE inhibitors in stroke patients - They have compelling indication for secondary stroke prevention, particularly when combined with diuretics 2, 3

2. Don't use ACE inhibitor + ARB combination - This is explicitly not recommended in stroke patients (Grade B) 2

3. Don't use short-acting nifedipine - Contraindicated (Grade D) 2

4. Don't undertreate due to age - Elderly stroke patients benefit significantly from BP control; use frailty assessment, not age alone, to guide targets 1

5. Don't delay treatment - At 6 months post-stroke, there is no reason to withhold or delay optimal antihypertensive therapy 2, 6

Monitoring Strategy

• Achieve target BP within 3 months of treatment initiation 1
• Use once-daily dosing and single-pill combinations to improve adherence 1
• Monitor for hyperkalemia if using ACE inhibitor/ARB, especially when adding spironolactone 4

Special Considerations

If patient has concurrent conditions:

• Diabetes: Same BP target <130/80 mmHg applies 1
• Chronic kidney disease: ACE inhibitors/ARBs are beneficial but require close monitoring 3
• Atrial fibrillation: Ensure appropriate anticoagulation in addition to BP control 8

The evidence strongly supports aggressive BP management in post-stroke patients to prevent recurrence, with the ACE inhibitor (or ARB) + diuretic combination forming the foundation of therapy, escalating systematically if targets are not met.